Edgewise Therapeutics, Inc. EWTX
46.53 USD -2.21 (-4.53%)
At closeNov 10, 2026, 6:52 PM EST
46.25 -0.28 -0.60%
After hours · Nov 10, 6:52 PM ET
44.79 Day range 47.79
18.28 52-week range 48.74
- YTD
- +87.47%
- 1 year
- +154.54%
News
prnewswire.com Edgewise Therapeutics to Participate in Upcoming Investor Conferences BOULDER, Colo., Nov. 9, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced that management will…
benzinga.com Wedbush Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $51 Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and lowers the price target from $53 to $51.
benzinga.com Edgewise Therapeutics Says Edgewise Has Submitted STRATUS-HCM Phase 3 Protocol Following End-Of-Phase 2 Meeting – STRATUS-HCM includes two independent placebo-controlled studies of symptomatic obstructive and nonobstructive HCM populations under a single master protocol, with peak VO₂ as the primary endpoint…
prnewswire.com Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring – Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability – – STRATUS-HCM includes two…
benzinga.com Edgewise Therapeutics Q3 Adj. EPS $(0.19) Misses $2.48 Estimate Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $2.48 by 107.66 percent. This is a 51.28 percent increase over losses…
prnewswire.com Edgewise Therapeutics Reports Third Quarter 2026 Financial Results – Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain – – Phase 3 trial for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy…
prnewswire.com Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules BOULDER, Colo., Nov. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today…
benzinga.com William Blair Initiates Coverage On Edgewise Therapeutics with Outperform Rating William Blair analyst Alethia Young initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform rating.- benzinga.com Edgewise Therapeutics Doses First Participant In EQUINOX-HFpEF Study Of EDG-15400 To Treat Adults With Symptomatic Heart Failure With Preserved Ejection Fraction Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiometabolic diseases, today announced the dosing of the first patient in EQUINOX-HFpEF, a…
prnewswire.com Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400 – Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at least 50% – – EQUINOX-HFpEF trial design and EDG-15400 Phase 1 first-in-human data to be presented at HFSA 2026…
prnewswire.com Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules BOULDER, Colo., Oct. 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular…
seekingalpha.com Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript
prnewswire.com Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500 - The MoA that targets the Regulatory Light Chain (RLC) has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve - - Company to host…- benzinga.com HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $57 HC Wainwright & Co. analyst Lander Egaña Gorroño maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $45 to $57.
schaeffersresearch.com Biotech Options Buzz: UTHR, NMRA, EWTX Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporation (NASDAQ: UTHR), Neumora Therapeutics Inc (NASDAQ: NMRA), and Edgewise Therapeutics Inc (NASDAQ:…
defenseworld.net 91,638 Shares in Edgewise Therapeutics, Inc. $EWTX Acquired by Hsbc Holdings PLC Hsbc Holdings PLC purchased a new position in shares of Edgewise Therapeutics, Inc. (NASDAQ: EWTX) in the second quarter, according to the company in its most recent filing with the Securities and…
prnewswire.com Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules BOULDER, Colo., Sept. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular…
prnewswire.com Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 – Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – BOULDER, Colo., Aug. 24,…
seekingalpha.com Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform Edgewise Therapeutics (EWTX) has transformed into a well-capitalized cardiovascular drug developer following the $1.55B sale of sevasemten to Servier. EDG-7500, EWTX's lead asset, demonstrated robust…- benzinga.com Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36 Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and raises the price target from $32 to $36.
- benzinga.com Edgewise Therapeutics Q2 EPS $(0.53) Misses $(0.47) Estimate Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.47) by 12.77 percent. This is a 55.88 percent decrease over…
prnewswire.com Edgewise Therapeutics Reports Second Quarter 2026 Financial Results – Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – – Completed sale of sevasemten and…
benzinga.com Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $55 Evercore ISI Group analyst Cory Kasimov maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $45 to $55.
prnewswire.com Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline — Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones — — Transaction creates strategically focused cardiovascular…
benzinga.com Oppenheimer Initiates Coverage On Edgewise Therapeutics with Outperform Rating, Announces Price Target of $51 Oppenheimer analyst Mazahir Alimohamed initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform rating and announces Price Target of $51.- benzinga.com Guggenheim Maintains Buy on Edgewise Therapeutics, Raises Price Target to $51 Guggenheim analyst Debjit Chattopadhyay maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $41 to $51.
prnewswire.com Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules BOULDER, Colo., July 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel…
benzinga.com Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax target increased, Sezzle target up, Biogen target raised, Progressive target cut.
benzinga.com RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $59 RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $48 to $59.- benzinga.com Delta Air Lines To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday Top Wall Street analysts changed outlook on top names. Baird raised prices for Ryder System and J B Hunt, Needham for Glaukos, B of A for CSX, Morgan Stanley for Charles River, and Bernstein for…
benzinga.com Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $32 Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and raises the price target from $20 to $32.
seekingalpha.com Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript
benzinga.com Edgewise Therapeutics Reports Improvements In Heart Drug Trial Edgewise Therapeutics Inc. (NASDAQ:EWTX) on Tuesday released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial.
benzinga.com Edgewise Therapeutics Reports Improvements In Heart Drug Trial Edgewise reports Phase 2 EDG-7500 data in thick heart muscles, showing symptom, biomarker, and heart function improvements.- benzinga.com HC Wainwright & Co. Reiterates Buy on Edgewise Therapeutics, Maintains $45 Price Target HC Wainwright & Co. analyst Lander Egaña Gorroño reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and maintains $45 price target.
reuters.com Edgewise shares slip after heart-disease drug trial data disappoints investors Edgewise Therapeutics shares fell nearly 10% on Tuesday after the efficacy of its experimental heart-disease drug in a mid-stage study fell short of investor expectations.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com Edgewise Therapeutics Says Topline Data From 12-week Phase 2 Part D CIRRUS-HCM trial of EDG-7500 In Obstructive And Nonobstructive Hypertrophic Cardiomyopathy Show No Relationship Observed Between Multiple Measures Of Systolic Function And Concentration Of EDG-7500 – No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% –– Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers,…
prnewswire.com Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) – No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers,…- benzinga.com HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $45 HC Wainwright & Co. analyst Lander Egaña Gorroño maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $42 to $45.
- benzinga.com RBC Capital Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $48 RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and lowers the price target from $50 to $48.
- benzinga.com Wedbush Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $52 Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $46 to $52.
benzinga.com Optimum Communications, Fluence Energy, Virgin Galactic And Other Big Stocks Moving Higher Today Several stocks, including Optimum Communications Services, surged while Dow fell. Technology, energy, and aerospace stocks saw notable gains.- benzinga.com Edgewise To Sell Its Muscular Dystrophy Business To Servier For $1.55B In Cash Up Front And Up To $1.1B In Further Milestone Payments For Aggregate Potential Sum Of Up To $2.65B The transaction meaningfully strengthens Edgewise's balance sheet, providing enhanced financial flexibility and sharpening the Company's strategic focus to accelerate and unlock the full potential of…
benzinga.com Rockwell Automation Posts Upbeat Q2 Results, Joins EverQuote, DigitalOcean And Other Big Stocks Moving Higher On Tuesday Dow Jones up 200 points, Rockwell Automation shares rise 10.8% on strong earnings and raised guidance. Other big gainers include EverQuote, Sterling Infrastructure, and DigitalOcean.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com Gold Edges Lower; Omeros Shares Jump
benzinga.com Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com 10 Health Care Stocks Whale Activity In Today's Session